News

June 7, 2023

Gilbert Technologies Completes Series A Investment Round

Dutch MedTech Company Gilbert Technologies Raises €7 Million Series A to Redefine Treatment for Lung Patients.

Eindhoven, The Netherlands, June 7 2023 – Gilbert Technologies, today announced the completion of its €7 million Seed – and Series A investment round. The investment rounds are led by Dutch deeptech investor DeeptechXL and joined by existing shareholders NanoCorp and Delft Enterprises.

Click here for the full press release.

February 21, 2022

Organizational Update

Gilbert Technologies names Scott Fleming Chief Commercial Officer. Click here for the full press release.

January 31, 2022

Organizational Update

Gilbert Technologies Announces George Hersbach to serve as Executive Chairman and Transition Role of CEO to Current COO Maurits Huigen. Click here for the full press release.

January 8, 2020

Interview with Maurits Huigen

Interview with our COO Maurits Huigen after the nomination of Gilbert Technologies as one of the promising respiratory device solution providers by Medical Tech Outlook Magazine.

January 2, 2020

Medical Tech Outlook Magazine

Gilbert Technologies has been listed as one of the pioneering respiratory device solution providers by Medical Tech Outlook Magazine. Read the article on Med Tech Outlook.

Press Release November 28, 2019

Funding for the development of a new generation soft mist inhalers for expensive medicines

The startup company Gilbert R&D B.V., a subsidiary of Gilbert Technologies B.V., announces today that it has received funding for the development of a new generation soft mist inhalers for the precise administration of expensive medicines for people with lung disease. Gilbert has received financing from Brabant Startup Fonds B.V. (“BSF”).

English: Click here for the full text press release.
Dutch: Click here for the full text press release.

PRESS RELEASE October 15, 2019

Belgium UCLouvain Louvain Drug Research Institute (LDRI) and Netherlands MedTech Start-up Gilbert Technologies join efforts for improved therapy for Cystic Fibrosis Patients.
LDRI receives funding for the development of a long-acting PEGylated rhDNase for CF-treatment with reduced therapeutic burden.
Click hiere for the full text press release.

Redefining Pulmonary Drug Administration and Therapy Adherence

MedTech Magazine, December 2018

When it comes to pulmonary drug administration and therapy adherence, it is noted that many of the commercially available inhalers such as Dry Powder Inhalers (DPIs) and Metered Dose Inhalers (MDIs) are relatively limited in their effectiveness. In this article, Maurits Huigen explains why and how Gilbert Technologies solves the limiting effects of current inhalers with a new finding using an electrospraying technique.
Read the full article published on Med Tech Outlook.

PRESS RELEASE

2018 Top 20 MedTech listing

We are proud to have received our listing in the Top 20 MedTech Solution Providers in Europe in October 2018 .
This is a huge inspiration to continue with our work to unlock the potential of our EHDA technology or patients for aerosolization and drug targeting o more complex and advanced molecular entities for respiratory and non-respiratory diseases. Also, this is an inspiring recognition for the Gilbert Team, our shareholders and our development partners.

Biotech and Life Sciences News

Gilbert Technologies, een spin-off van de TU Delft die zich richt op de ontwikkeling van haar innovatieve en gepatenteerde EHDA inhalatietechnologie, staat aan de vooravond van haar eerste grote investeringsronde met Ekoy Investment Partners.

De, op basis van nanotechnologie gebaseerde, Elektrohydrodynamische Atomisatie (EHDA) technologie heeft de potentie unieke voordelen aan patiënten te bieden voor aerosolisatie en targetting van meer complexe en geavanceerde geneesmiddelen  zoals bijvoorbeeld biologicals, cytostatica en fibroseremmers.

Met deze zogenaamde ‘electrospray’ kunnen aerosolen in deeltjesgrootte variëren, waardoor, afhankelijk van het ziektebeeld en de toe te dienen medicatie, het geneesmiddel nauwkeurig lokaal kan worden getarget in de luchtwegen. De druppelgrootte kan binnen een smal interval worden geregeld, waardoor een uniforme en monodisperse aerosol ontstaat. Met de gecontroleerde druppelgrootte kan het medicijn op de juiste plaats in de longen worden afgegeven, wat resulteert in relevante klinische voordelen.

Bron: Biotech News & Life Sciences, 17e Jaargang – Nummer 1 – Mei 2018, p. 28
Lees hier op pagina 28: biotechnews_mei_2018